---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-051876"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:50:33.225090+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica Q4 2023 YCANTH revenue $1.9M; net loss $24.6M vs $5.9M prior year

## Summary
- Full-year 2023 YCANTH product revenue $4.7M; first commercial revenue after Q3 2023 launch.
- Net loss FY 2023 $67.0M ($1.48 per share) vs $24.5M ($0.72 per share) in FY 2022; non-GAAP net loss $51.8M ($1.14 per share).
- SG&A expenses surged to $47.3M for FY 2023 (FY 2022: $17.4M) driven by commercial ramp and stock compensation.
- Cash and equivalents $69.5M as of Dec 31, 2023; runway into Q2 2025.
- CMS issued permanent J-code for YCANTH (effective Apr 1, 2024); FDA aligned on Phase 3 design for common warts; VP-315 Phase 2 top-line data expected H1 2024.

## SEC filing metadata
- accession: 0001193125-24-051876
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/0001193125-24-051876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/d795567d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-051876
- JSON: https://secwatch.observer/filing/0001193125-24-051876.json
- Plain text: https://secwatch.observer/filing/0001193125-24-051876.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/0001193125-24-051876-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.